Palmitoyl rhizoxin | CAS#135819-69-1 | antitumor agent

MedKoo Cat#: 461308 | Name: Palmitoyl rhizoxin

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Palmitoyl rhizoxin is a highly lipophilic antitumor agent.

Chemical Structure

Palmitoyl rhizoxin

CAS#135819-69-1

Theoretical Analysis

MedKoo Cat#: 461308

Name: Palmitoyl rhizoxin

CAS#: 135819-69-1

Chemical Formula: C51H77NO10

Exact Mass: 863.5547

Molecular Weight: 864.17

Elemental Analysis: C, 70.88; H, 8.98; N, 1.62; O, 18.51

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

Palmitoyl rhizoxin; RS-1541; RS 1541; RS1541;

IUPAC/Chemical Name

(1S,3R,5S,8R,10S,11R,13S,16R,17S,E)-8-((2S,3S,4E,6E,8E)-3-methoxy-4,8-dimethyl-9-(2-methyloxazol-4-yl)nona-4,6,8-trien-2-yl)-11,16-dimethyl-6,19-dioxo-4,7,12,18-tetraoxatetracyclo[15.3.1.03,5.011,13]henicos-14-en-10-yl palmitate

InChi Key

ZFYKZAKRJRNXGF-QDIPDBMKSA-N

InChi Code

InChI=1S/C51H77NO10/c1-9-10-11-12-13-14-15-16-17-18-19-20-21-25-46(53)61-45-32-42(37(5)48(56-8)36(4)24-22-23-34(2)28-40-33-57-38(6)52-40)60-50(55)49-43(59-49)30-39-29-41(58-47(54)31-39)35(3)26-27-44-51(45,7)62-44/h22-24,26-28,33,35,37,39,41-45,48-49H,9-21,25,29-32H2,1-8H3/b23-22+,27-26+,34-28+,36-24+/t35-,37+,39+,41+,42-,43-,44+,45+,48-,49+,51+/m1/s1

SMILES Code

CCCCCCCCCCCCCCCC(O[C@H]([C@@]1(C)O[C@@]1([H])/C=C/[C@@H](C)[C@@]2([H])O3)C[C@H]([C@@H]([C@H](OC)/C(C)=C/C=C/C(C)=C/C4=COC(C)=N4)C)OC([C@@]5([H])O[C@]5([H])C[C@@](C2)([H])CC3=O)=O)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.03.00

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 864.17 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Kurihara A, Shibayama Y, Mizota A, Yasuno A, Ikeda M, Hisaoka M. Pharmacokinetics of highly lipophilic antitumor agent palmitoyl rhizoxin incorporated in lipid emulsions in rats. Biol Pharm Bull. 1996 Feb;19(2):252-8. PubMed PMID: 8850317. 2: Tokui T, Kuroiwa C, Tokui Y, Sasagawa K, Kawai K, Kobayashi T, Ikeda T, Komai T. Contribution of serum lipoproteins as carriers of antitumour agent RS-1541 (palmitoyl rhizoxin) in mice. Biopharm Drug Dispos. 1994 Mar;15(2):93-107. PubMed PMID: 8011970. 3: Kurihara A, Shibayama Y, Kasuya A, Ikeda M, Hisaoka M. Species variation in pharmacokinetics and opsonization of palmitoyl rhizoxin (RS-1541) incorporated in lipid emulsions. J Drug Target. 1998;5(6):491-505. PubMed PMID: 9783680. 4: Kurihara A, Shibayama Y, Mizota A, Yasuno A, Ikeda M, Sasagawa K, Kobayashi T, Hisaoka M. Enhanced tumor delivery and antitumor activity of palmitoyl rhizoxin using stable lipid emulsions in mice. Pharm Res. 1996 Feb;13(2):305-10. PubMed PMID: 8932454. 5: Tokui T, Maeda N, Kuroiwa C, Sasagawa K, Inoue T, Kawai K, Ikeda T, Komai T. Tumor selective effect of RS-1541 (palmitoyl-rhizoxin) in M5076 sarcoma and host tissues in vivo. Pharm Res. 1995 Mar;12(3):370-5. PubMed PMID: 7617523. 6: Takatori T, Koizumi T, Tokui T, Mitsuhashi Y, Shiraishi A, Tsuruo T. Intracellular activation and cytotoxic action of RS-1541 against cultured human tumor cells. Cancer Chemother Pharmacol. 1995;35(4):283-90. PubMed PMID: 7828270. 7: Tokui T, Takatori T, Shinozaki N, Ishigami M, Shiraishi A, Ikeda T, Tsuruo T. Delivery and cytotoxicity of RS-1541 in St-4 human gastric cancer cells in vitro by the low-density-lipoprotein pathway. Cancer Chemother Pharmacol. 1995;36(1):1-6. PubMed PMID: 7720169. 8: Kurihara A, Shibayama Y, Mizota A, Yasuno A, Ikeda M, Sasagawa K, Kobayashi T, Hisaoka M. Lipid emulsions of palmitoylrhizoxin: effects of composition on lipolysis and biodistribution. Biopharm Drug Dispos. 1996 May;17(4):331-42. PubMed PMID: 8743404. 9: Kurihara A, Shibayama Y, Yasuno A, Ikeda M, Hisaoka M. Lipid emulsions of palmitoylrhizoxin: effects of particle size on blood dispositions of emulsion lipid and incorporated compound in rats. Biopharm Drug Dispos. 1996 May;17(4):343-53. PubMed PMID: 8743405.